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Abstract  
Background: Glioblastoma (GBM) patients currently face poor survival outcomes with 
an average survival rate less than 15 months with treatment (radiation and 
temozolomide), while only 3-5% of patients survive more than 36 months (1). Although 
the mechanisms underlying tumor development and progression are still being 
elucidated, microRNAs (miRNAs) are promising candidates to explore as novel   
biomarkers and therapeutic targets in GBM due to their size, stability, and myriad of target 
genes (2). Previously, in a univariable analysis, our lab showed that higher levels of miR-
575 were significantly associated with worse overall survival in GBM patients (HR: 1.3; p-
value: 5.77E-05; FDR p-value: 0.0036). Additionally, miR-575 was found to be 
significantly associated with worse overall survival independent of age, gender, treatment 
and KPS (Karnofsky’s Performance Status) in a multivariable analysis (HR: 1.2; p: 0.012; 
95% CI (1.04-1.4)). Based on this preliminary finding, we hypothesized that miR-575 acts 
as an oncogene in GBM. 
Methods: Cell proliferation, colony formation, and migration assays were performed to 
investigate the physiological role of miR-575 in GBM cell lines. qPCR, immunoblots, and 
luciferase assays were performed to validate the downstream targets of miR-575, 
determined by in silico database analyses. Clonogenic assays and cell viability assays 
were then used to assess the effect of miR-575 on radiosensitivity and chemosensitivity, 
respectively. 
Results: Overexpression of miR-575 significantly increased cell proliferation and cell 
motility in different GBM cell lines in vitro. p27/CDKN1B and BLID/BRCC2, both tumor-
suppressor genes, were identified as putative targets of miR-575 and their expression 
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was inversely correlated with miR-575 in vitro. No clear effect of miR-575 was observed 
on radiosensitivity and chemosensitivity.  
Conclusion: Our results suggest that miR-575 may serve as a novel prognostic 
biomarker in GBM, with higher expression correlating with worse overall survival. miR-
575 likely acts as an oncogene by targeting tumor-suppressor genes p27 and BLID. 
Knowledge of the role of miR-575 in tumor progression as well its underlying mechanisms 
may improve determination of prognosis and treatment response in GBM. Future work 
will focus on validating miR-575 as a prognostic biomarker in an independent GBM 
cohort. The physiological study of miR-575 should be replicated in primary glioma cell 
lines prior to in vivo experiments. Furthermore, additional target genes were identified 
during in silico analyses that should be investigated for further elucidation of the 
mechanisms underlying the oncogenic effect of miR-575 in GBM.  
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Relevance 
Under the current treatment regimens, including surgical resection, chemotherapy, 
and radiation therapy, median overall survival times remain poor for GBM patients. Novel 
therapeutic approaches are desperately needed for survival and quality of life 
improvements in GBM patients. Due to heterogeneity in GBM, tumors within the same 
histological category demonstrate variations in prognoses and responses, although 
collectively GBMs result in poor clinical outcomes. (3). Therefore, identification of novel 
biomarkers is necessary in order to molecularly characterize these tumors, rather than 
pathologically, so that more personalized, effective treatments can be delivered. While 
biomarkers are already being utilized in GBM, such as MGMT methylation status, a multi-
faceted approach from proteomics, genomics, and epigenetics will improve the 
effectiveness of the current classification system in the temozolomide era (4). 
miRNAs are ideal biomarker candidates due their stability in formalin-fixed paraffin 
embedded (FFPE) tissue and biofluids, as well as the affordability of their assays. 
Biologically, miRNAs are also exciting therapeutic candidates as they are capable of 
having a more global effect due to their myriad of target genes, many of which are 
oncogenes and tumor-suppressor genes. Dysregulated miRNAs are known to contribute 
to tumor progression in cancers through cell cycle, apoptosis, invasion, and cell 
metabolism (2). Therefore, elucidation of the mechanisms by which miRNAs regulate 
tumor development and progression is essential to better understand the pathogenesis 
of GBM. 
The identification of significant miRNAs in GBM has the potential to improve overall 
survival of patients through more accurate risk classification, and with a better 
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understanding of the underlying biology of GBM, novel therapies will be developed and 
implemented in the clinic. Additionally, the relevance of this miRNA study extends beyond 
GBM, for significant microRNAs are often implicated in multiple cancers (2). 
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Aims 
 
The aims of this project are to validate the biological significance of miR-575 in vitro using 
GBM cell lines and determine whether these findings have the potential to impact 
prognosis, treatment response, or novel therapeutic approaches in glioblastoma.  
Aim 1: Validate the physiological role of miR-575 in GBM and underlying mechanisms in 
vitro. Based on clinical data showing that higher miR-575 expression levels were 
associated with worse overall survival, GBM cell lines will be used to assess effects of 
miR-575 on aspects of tumor progression and to determine its target genes. We 
hypothesize that miR-575 will have an oncogenic effect in GBM by down-regulating tumor 
suppressor genes. 
Aim 2: Determine the effect of miR-575 on therapeutic sensitivity. miR-575 expression 
levels will be assessed in GBM cell lines treated with either temozolomide or radiation 
therapy. We hypothesize that miR-575 expression might predict response in both 
temozolomide and radiation therapy due to its correlation with worse overall survival in 
our GBM patient cohort.  
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Introduction 
1. Glioblastoma 
1.1 Background 
Glioblastoma (GBM) is the most aggressive brain tumor, a grade IV glioma, with an 
average survival rate of 15 months with standard treatment (3). The incidence of GBM in 
the U.S. is 2-3 per 100,000 (5). GBM is typically detected using magnetic resonance 
imaging (MRI), and if possible, surgical resection is done first to remove the majority of 
the tumor and biopsy the tumor for diagnosis. GBM is assessed histologically by the WHO 
guidelines, based on necrosis and microvascular proliferation (6). Currently, GBM is 
treated according to the Stupp protocol, which includes radiotherapy plus concomitant 
and adjuvant temozolomide (TMZ). 
Differences in survival times indicate that a subset of patients may have molecular 
features that produce more favorable outcomes. This underlying heterogeneity warrants 
the use of molecular biomarkers to better stratify patients for treatment and determine 
prognosis (4, 7-9). Some molecular biomarkers are currently assessed at diagnosis in 
GBM, including isocitrate hydrogenase (IDH), O6-methylguanine-DNA-methyltransferase 
(MGMT) methylation, and ATRX status (6). 
1.2 Classification 
The 2016 World Health Organization (WHO) Classification of Gliomas proposes that 
glioblastomas should be classified both histologically and genetically in order to improve 
prognostic outcomes and treatment responses. This was the first time that molecular 
markers were incorporated into the diagnosis of brain tumors. Diffuse glioma classification 
now separates astrocytomas and glioblastomas based on the presence of IDH1/2 gene 
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mutations. Additionally, the 1p/19q codeletion is now required for oligodendroglioma 
diagnosis in addition to the IDH1/2 gene mutation (10). 
Importantly, glioblastomas are classified as either primary or secondary tumors. 90% 
of GBMs are primary or de novo, meaning that the tumor developed rapidly without 
evidence of precursor lesions. In contrast, secondary GBM is a progression of a less 
malignant tumor, usually a diffuse or anaplastic astrocytoma (9). Additionally, secondary 
GBMs tend to yield more favorable outcomes. While primary and secondary GBMs are 
histologically similar, important genetic and epigenetic differences distinguish the 
subtypes. Overall, secondary GBMs are more genetically homogenous, while primary 
GBMs express greater heterogeneity (9). 
GBMs are further classified based upon cDNA expression profiles as either proneural, 
neural, classical, or mesenchymal. These subtypes are defined by the tumor’s precursor 
cell type and further classified by genetic differences (9, 11, 12). Different subtypes of 
GBM have been shown to respond differently to treatment, temozolomide and radiation 
therapy. Thus, it is crucial to further define these subtypes using molecular markers. 
Additionally, molecular markers aid in understanding GBM pathogenesis, which can 
provide key insight into more efficacious interventions (11). 
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1.3 Notable Genetic Alterations 
           Genetic alterations of GBM are summarized in Figure 1. Primary and secondary 
GBM possess key genetic differences. In primary GBM, EGFR is amplified, PTEN is often 
mutated, and chromosome 10q is lost. In contrast, TP53 is typically mutated and 
chromosome 19q is lost in secondary GBM (9, 11). 
 However, IDH1 has emerged as the main gene to differentiate the two subtypes. 
Less than 10% of primary GBMs have IDH mutations. In contrast, over 80% of secondary 
GBMs have IDH1 mutations (13). In primary GBM, IDH1/2 mutations actually yield more 
favorable outcomes than IDH1/2 wildtype. GBM patients with IDH1/2 mutations have an 
average survival of 31 months, while IDH1/2 wildtype patients have an average survival 
of 15 months (13). While this mechanism remains unclear, one possibility is that this could 
Figure 1: Genetic alterations differentiate primary and secondary glioblastoma and 
contribute to disease progression (http://clincancerres.aacrjournals.org). 
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be due to decreased migratory ability in the mutant tumors, or a negative effect on the 
tumor posed by 2HG production (13). Interestingly, IDH1 mutations are relied upon more 
heavily for diagnosis than histological observation; this is yet another instance of the 
significance of genetic alterations in GBM (9). More biomarkers are necessary to further 
identify GBM subtype and increase our understanding of the mechanisms underlying 
tumor progression.  
1.4 Biomarkers in GBM 
While IDH1/2 mutations permit the molecular classification of GBMs, biomarkers can 
also predict treatment response. Notably, biomarkers like MGMT promoter methylation 
status indicate differential survival times and response to chemotherapy. Patients with 
MGMT promoter hypermethylation experience longer survival times due to the effect of 
MGMT on temozolomide treatment (14). Temozolomide acts by methylating DNA, which 
is prevented when MGMT is methylated resulting in reduced MGMT protein levels. While 
MGMT in its active form can reverse the TMZ-induced alkylated bases, MGMT 
methylation reverses this process by depleting MGMT protein levels. Thus, methylation 
allows temozolomide to cause a greater number of cells to undergo apoptosis, which 
leads to more favorable patient outcomes (14). More molecular biomarkers beyond 
MGMT, including miRNA signatures, will help to further stratify patients into more specific 
and accurate groups, which will ultimately improve clinical decision-making (3, 8).  
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2. microRNAs as biomarkers in GBM 
2.21 miRNA Biogenesis 
Recently, miRNAs have emerged as promising and novel candidates for GBM 
biomarkers. miRNAs are small non-coding 
RNAs, about 22 nucleotides (nt) in length, that 
can lead to mRNA degradation or translational 
repression. miRNAs are often formed in areas 
of relaxed chromatin, known as euchromatin, 
which is often hypomethylated. In contrast, 
hypermethylated, tightly wound regions of 
chromatin, known as heterochromatin, are 
less likely to facilitate miRNA formation (2). In 
the nucleus, primary miRNA (pri-miRNA) is 
first transcribed by RNA polymerase II, as 
shown in Figure 1. Pri-miRNA then forms a 
hairpin loop shape and is capped and 
polyadenylated. Pri-miRNA is then cleaved by 
an RNAse endonuclease III called DROSHA 
and DiGeorge syndrome critical region gene 
8 (DGCR8), into pre-miRNA of approximately 
70 nt. This pre-miRNA is then transported into 
the cytoplasm via Exportin-5, which is a 
double-stranded binding protein. In the 
Figure 2: miRNA processing begins in 
the nucleus and ends in the cytoplasm. 
The enzymes RNA Pol II, DGCR8, 
DROSHA, Exportin-5, Dicer, AGO, and 
RISC are shown, respectively. 
Biogenesis results in a mature miRNA 
that can bind the 3’UTR of 
complementary mRNA (2). 
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cytoplasm, miRNA binds to the RNAse III endonuclease enzyme Dicer where it is cleaved 
into a mature, double-stranded RNA of approximately 22 bp (2, 7). One strand of the 
mature miRNA, known as the guide strand, is now free to bind an Argonaute (AGO) 
protein in the RNA Silence-Inducing Complex (RISC). The strand of the miRNA duplex 
chosen as the guide strand is thought to be the strand with the less tightly bound 5’ end. 
Helicase samples both 5’ ends and begins unwinding the easier of the two. This miRNA 
bound to RISC may now bind to complementary sequences, most commonly in the 3’UTR 
of target mRNAs (15). 
2.22 miRNA targeting  
Once bound to mRNA, miRNA may either cleave mRNA or block translation 
without cleavage. High complementarity between miRNA and mRNA typically leads to 
cleavage and subsequent degradation (16). Cleavage occurs at the 10th or 11th 
nucleotide, regardless or complementarity. However, low complementarity facilitates 
translational blockage without cleaving mRNA. This phenomenon is exhibited in Figure 
3. miRNA will remain intact after mRNA cleavage. In fact, miRNA is more stable than 
RNA in adverse conditions. miRNA can be packaged extracellularly and is usually bound 
to an RNA-binding protein or a lipoprotein complex (7, 15). 
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2.23 Benefits and limitations of miRNAs in the clinic  
 In the past decade, numerous studies have noted the relevance of aberrant miRNA 
expression in cancer due to their ability to promote angiogenesis, invasion, and 
metastasis through control of oncogenes and tumor-suppressor genes (16).  miRNAs 
help to further elucidate oncogenic pathways, which provide additional gene targets for 
therapeutic innovation. Individual miRNAs and miRNA expression profiles are now being 
studied for their uses in diagnosis, prognosis, and therapeutics. (17). While many studies 
have highlighted the exciting potential of miRs as biomarkers and therapeutic agents, 
several obstacles must be overcome before miRs can be effectively implemented in the 
clinic for GBM. 
Traditional methodologies of cancer diagnosis involve histological classification 
following biopsy. Since miRNAs are readily found in the blood and urine, miRNA analyses 
can be performed non-invasively and inexpensively (2). The novelty of using microRNAs 
as biomarkers lies in their high intrinsic stability in the bloodstream and cerebrospinal fluid 
(CSF). MiRNAs are more stable than their RNA counterpart in relatively hot or acidic 
Figure 3: Small silencing RNAs, either miRNAs or siRNAs, can act in several distinct 
mechanisms depending on complementarity with mRNA. miRNAs can act via 
cleavage (A), translation repression (B), or transcriptional silencing (C) (16).  
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conditions making them more amenable to FFPE-based assays. Additionally, miRNAs 
have a very low molecular weight, which makes them good candidates for delivery in 
therapeutics (2). MicroRNAs would allow for non-invasive diagnosis and serve as 
indicators of prognosis and treatment response (2, 7, 8). Individual miRNAs and miRNA 
expression profiles are associated with survival patterns in GBM. Current miRNA reviews 
indicate that the ideal use of miRNAs as biomarkers lies in signatures consisting of 
multiple microRNAs that are differentially expressed in GBM compared to normal tissues 
and distinct from other cancers (8). Additionally, microRNAs can be used to distinguish 
between GBM subclasses (8, 12). A recent study used 261 microRNAs to distinguish five 
subclasses of glioblastoma and have reported that microRNAs enhance the ability to 
distinguish between different classes of GBM both histologically and prognostically (12).  
Currently, studies involving miRNAs are highly variable, meaning that a double-
headed approach utilizing bioinformatics and molecular studies is necessary (8). For use 
as a gene therapy, miRNAs are exciting candidates as they are capable of having a more 
global effect due to their myriad of target genes, many of which are oncogenes and tumor-
suppressor genes.  
While the risks of using miRNAs as biomarkers are minimal, the use of miRNAs as 
therapies could cause off-target effects and toxicity to the patient (7, 8). There are 
additional limitations to consider when proposing miRNAs as therapeutic agents. 
Specifically for gliomas, there could be additional challenges in delivery due to the highly 
selective blood-brain barrier. Lastly, even once the miRNA is the brain, it may be another 
challenge to get the miRNA inside the cell due to high interstitial pressure of tumor cells 
(7). 
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Additional concerns surround the validity of miRNAs as biomarkers. While several 
miRNAs maintain consistent expression, there are inconsistent data regarding miRNA 
expression between GBM tissue and serum (8). Furthermore, miRNA expression profiles 
obtained from serum could eventually help distinguish cancer types without biopsy (8). 
2.24 miRNA in clinical trials 
While there are no current miRNA clinical trials in glioma, miRNA therapies have 
reached clinical trials in other cancers and diseases (18-20). The first microRNA to reach 
a Phase II clinical trial was antimiR-122 for treatment of hepatitis C virus infection (18). 
The study of the antisense oligonucleotide would be used in conjunction with other current 
therapies. Specifically in cancer, two miRs have recently reached Phase III clinical trials. 
MiR-34 (MRX34) was the first miRNA to reach Phase I clinical trial for patients with liver 
cancer. However, the study was terminated in 2016 after five adverse immune responses 
occurred (21). Another study completed in 2017 utilized EGFR-targeted miR-16-based 
miRNA for treatment in pleural mesothelioma and non-small cell lung cancer. While the 
results of this study have not yet been published, this miRNA therapy did pass initial safety 
trials (19). 
2.25 Delivery Systems 
MicroRNA mimics and anti-miRs are used for transfection into mammalian cell 
lines for physiological and therapeutic studies in vitro. They also serve as potential 
therapeutic strategies in vivo. Anti-miRs are single stranded miRNA passenger strands 
that bind to the active miRNA strand, which is now left unable to be processed by RISC. 
In contrast, mimics act as endogenous double-stranded miRNAs. Both are low molecular 
weight oligonucleotides (2, 7). Both mimics and anti-miRs would need to be chemically 
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modified prior to delivery to avoid degradation by nucleases. Figure 4 shows the action 
of both miRNA mimics and anti-miRs with target mRNA. 
 Other therapeutic opportunities for miRNA include miRNA masks and miRNA 
sponges. miRNA masks are single-stranded and bind perfectly to the miRNA’s target in 
mRNA 3’UTR. In this therapy, miRNA is not degraded, so off target effects are 
diminished. On the other hand, miRNA sponges include multiple sites for miRNA 
binding and sequester it away from the target gene (7).  
For delivery of this miRNA replenishment and inhibition molecules, lentiviruses, 
adenoviruses, or nanoparticles may serve as promising options.  
3. Validating miRNAs in GBM 
3.1 Identifying clinically relevant miRNAs 
Figure 4: Mimic and antagonist structure and effect on microRNA activity and 
subsequent gene expression (http://www.aptamir.com). 
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If miRNAs are implemented in the clinic, there are several options for detection in 
patient serum. Likely techniques that would be used to detect miRNAs would be 
Nanostring, microarray, next generation RNA sequencing (NGS), and RT-qPCR. 
Microarrays can detect a more widespread effect, however, RT-qPCR is much more 
specific and is recommended for diagnostic purposes (8).  
In this study, and in other clinical studies, Nanostring was utilized for widespread 
detection of miRNA in FFPE samples. However, for detection of miRNA expression levels 
within the laboratory, RT-qPCR techniques are more commonly used due to its 
robustness, cost-effectiveness, and routine use.  
3.2 Aspects of tumorigenesis affected by miRNAs 
In order to validate a microRNA in vitro for GBM, its physiological effect on 
tumorigenesis must be elucidated. miRNAs can target pathways in many aspects of 
tumorigenesis, but miRNAs are known to be implicated in angiogenesis, invasion, and 
cell metabolism.  
Angiogenesis occurs in order to navigate more oxygenated blood to the tumor site. 
In a growing tumor, oxygen is used readily resulting in a hypoxic environment. The tumor 
must obtain more oxygen through increased availability of oxygenated blood. The 
mechanism of angiogenesis involves the release of pro-angiogeneic factors like vascular 
endothelial growth factor (VEGF) to increase blood vessel formation. However, during 
this rapid formation of blood vessels, inadequate formation occurs resulting in leaky blood 
vessels (8). These leaky blood vessels actually prevent the effective delivery of oxygen 
to the tumor site. In addition to oxygen, chemotherapy also cannot effectively reach the 
tumor site, which promotes treatment resistance (2, 7). Angiogenesis is a key component 
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of tumorigenesis that is targeted frequently in GBM due to its role in treatment resistance. 
Combatting angiogenesis may be an effective strategy for therapeutic intervention. 
Both miR-7 and miR-296 are implicated in glioma angiogenesis. Down-regulation 
of miR-7 inhibits angiogenesis, while up-regulation of miR-296 promotes angiogenesis 
(22, 23). miR-296 acts by targeting hepatocyte growth factor-regulated tyrosine kinase 
substrate (HGS) which degrades VEGFRs and promotes angiogenesis (7). miR-7 acts 
through the EGFR and PI-3K signaling pathways (7). 
Glioblastomas are highly invasive and infiltrate other neurons and glia, rather than 
metastasizing to other areas of the body. Due a high number of invasive cells, surgical 
resection and treatment delivery become increasingly difficult (7). Invasion occurs when 
GBM cells acquire a mesenchymal phenotype and migrate along blood vessels. The cells 
then extend from the extracellular matrix and spread to the parenchyma. Matrix 
metalloproteinases (MMPs) and uro-kinase type plasminogen activator (uPA) are also 
prominent factors in physiological invasiveness in GBM that act by degrading the 
extracellular matrix and promoting tumor invasion (ECM) (24). Another significant protein 
pathway in this mechanism is the hepatocyte growth factor (HGF) and its receptor c-MET 
(7). Interestingly, Bell et al. reported that increased levels of c-MET are associated with 
worse overall survival in GBM (4). 
Additionally, radiation therapy is known to increase the invasiveness of GBM cells. 
Increased invasion is observed following radiation therapy, which exhibits morphology 
distinct from physiological invasion (24). This impacts the efficacy of subsequent radiation 
as tumor cells have migrated outside the geographic field of radiation (24). The 
mechanism underlying radiation-induced invasion involves the EGFR/IGFR-1/PI-3K/Rho 
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signaling pathway, whose activation promotes invasion (24). These mechanisms serve 
as crucial targets for reduced invasion in GBM and improved treatment outcomes. 
miR-21, the first miR to be discovered in GBM, is up-regulated in GBM and 
contributes to invasion through down-regulation of MMP inhibitors (25). miR-10b is also 
up-regulated in GBM and promotes invasion through a mechanism involving RhoC and 
uPAR (7). The combination of these miRs has been suggested to be a valuable diagnostic 
tool in GBM when patients are treated with bevacizumab (BVZ), an alternate 
chemotherapy drug (8).  
Lastly, cell metabolism plays a major role in tumor formation, especially in gliomas 
(7). While we are not clear whether cell metabolism is a result or a cause of tumor 
formation, metabolic alterations are present in many cancer types including glioblastoma 
(13).  Cancer cells, in general, prefer aerobic glycolysis that converts glucose to lactate 
instead of pyruvate to bypass traditional oxidative phosphorylation for ATP production. 
This process is known as the Warburg Effect (13).  Lactate is used as carbon source for 
cell proliferation, as normal cells engage in aerobic glycolysis in times of increased 
proliferative activity (13). Mutations of isocitrate hydrogenase 1 or 2 (IDH1/2), have been 
shown to disrupt cell metabolism and are believed to be involved in carcinogenesis. 
Mutations in IDH1/2 lead to high levels of 2-hydroxyglutarate, which is thought to be an 
oncometabolite (13). IDH1/2 also play a key role in producing NADPH, a premier reducing 
agent outside the mitochondria. NADPH also protects against radiation and oxidative 
stress.  
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Notably, miR-153 is known to act as a tumor suppressor by promoting apoptosis, 
but it may also function through targeting of glutaminase, which prevents the cell from 
obtaining energy through glutamine and thereby prevents proliferation (7).  
4. miR-575 
4.1 Univariable and Multivariable Analysis of miR-575 on overall survival (OS) in GBM 
To generate miRNA expression data, a total of 268 FFPE tumor samples were 
provided from patients with newly diagnosed primary GBM (IDH-wild-type). These 
patients underwent biopsy or resection at the University of Utrecht, Netherlands from 
2005 to 2014.  Total RNA was isolated from these samples and used for further analyses. 
This study was approved by both University Medical Center Utrecht and The Ohio State 
University institutional review boards with waived patient consent due to the archival 
nature of the study.  
miRNA expression data was analyzed using the NanoString human v3 array 
developed by NanoString Technologies (Seattle, WA). Total RNA was used from 268 
tumor samples. Nanostring includes 798 miRNA probes, but miRs were filtered from this 
analysis if greater than 80% of the samples were missing the miR. MiR-575 was 
highlighted as one of the top miRNAs associated with overall survival in this cohort using 
univariable analysis (HR: 1.3; p-value: 5.77E-05; FDR p-value: 0.0036).  Figure 5 shows 
a Kaplan-Meier Survival Analysis of miR-575 expression with overall survival in this GBM 
patient cohort (HR: 1.5; log-rank p-value: 0.004). 
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In the multivariable analysis, miR-575 expression was assessed in the Utrecht 
patient cohort previously described (n=204). The sample size for the multivariable 
analysis is reduced compared to the univariable analysis because patients were excluded 
if they did not have information for all covariables. Table 1 shows multivariate statistical 
analysis of miR-575 expression in GBM patients based on age, treatment, gender, and 
all variables combined. As shown, miR-575 is a prognostic biomarker, which is 
independent of clinical variables in GBM (p: 0.012; HR: 1.21, 95% CI (1.04-1.4)). 
However, Table 2 shows that miR-575 expression level was not significant in a 
multivariable analysis when MGMT methylation status was included (p: 0.323; HR: 1.1; 
Figure 5: Correlation between miR-575 expression and overall survival by Kaplan-
Meier analysis of GBM patients with high (n=134) and low (n=134) expression of miR-
575 (HR: 1.3; p-value: 5.77E-05; FDR p-value: 0.0036).  
22  
95% CI (0.912-1.32)). This result suggests that the clinical utility of miR-575 is limited, 
since MGMT methylation is already used as a prognostic biomarker in GBM.  
4.2 Current knowledge of miR-575 
While miR-575 was found to be significantly correlated with worse overall survival 
in GBM based on our study, miR-575 has also been found to be implicated in gastric, 
lung, breast, and esophageal cancers [19-22]. No publications currently exist regarding 
miR-575 and gliomas to our knowledge. However, miR-575 has been shown to have both 
oncogenic and tumor suppressive effects in cancer. High expression of miR-575 is found 
Table 1: Multiple variable analysis of miR-575 expression using the following 
covariables: gender, age, treatment, and Kornofsky Performance Scale (KPS). miR-
575 was found to be significant independent of these variables (p: 0.012; HR: 1.21; 
95%CI (1.04-1.4)). 
Table 2: Multiple variable analysis of miR-575 expression using the following 
covariables: gender, age, treatement, Kornofsky Performance Scale (KPS), and 
MGMT methylation status. miR-575 was not found to be significant independent of 
these variables (p: 0.323; HR: 1.1; 95% CI (0.912-1.32). 
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in non-small cell lung cancer (NSCLC) tissues, and promotes cell proliferation, migration 
and invasion of NSCLC cells (26), but in breast cancer, miR-575 reduces cell growth and 
motility (27). miR-575 signature profiles have also been used to distinguish esophageal 
adenocarcinoma from Barrett’s esophagus, significantly impacting treatment 
decisions(28).  In addition, microarray analyses in lymphoblastoid cell lines suggest than 
miR-575 may be negatively associated with cell-cycle genes (29). Furthermore, miR-575 
is significantly upregulated in human gastric cancer (30).  
5. Summary 
Based on the preliminary clinical data, we hypothesized that miR-575 plays an 
oncogenic role in GBM tumorigenesis by inhibiting tumor-suppressor gene function either 
post-transcriptionally or post-translationally. Additionally, we hypothesize that miR-575 
contributes to treatment resistance in GBM. 
Herein, we sought to determine the role of miR-575 in proliferation, colony 
formation, and migration in GBM. In addition, we aimed to elucidate the molecular 
mechanisms that miR-575 targets. Lastly, we endeavored to determine the role of miR-
575 in therapeutic sensitivity in GBM. 
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Materials and Methods 
Cell Culture   
The GBM cell lines LN18, LN229, T98G, U251, and U87 were purchased from ATCC. 
Normal human astrocytes (NHA) were purchased from Lonza. U87/EGFRvIII cells were 
provided by Deliang Guo (The Ohio State University). All of these cell lines were grown 
in DMEM media (Gibco) with 10% (v/v) fetal bovine serum (FBS) and 100U/mL 
penicillin/streptomycin (Sigma). GBM30, a primary patient-derived cell line, was provided 
by Balveen Kaur (The Ohio State University). GBM30 cells were grown in a neurobasal 
medium, supplemented with B27 (1×), Heparin (2µg/ml), EGF (20ng/ml), and FGF 
(20ng/ml). All cells were cultured in a 5% CO2 sterile environment at 37oC. 
Transfection of miRNA mimics, inhibitors and anti-miRNAs 
Twenty-four hours prior to transfection, 3 X 105 cells were seeded into 60 mm dishes. 
Cells were counted using a manual cell counter. The total cell number in all four quadrants 
was averaged and multiplied by 104 cells/mL. Media was first aspirated from 60 mm 
dishes and replaced with DMEM media containing 10% FBS and no antibiotics before 
transfection. Opti-MEM media (Gibco), Lipofectamine 2000 (Invitrogen), and miR-575 
mimic, inhibitor and anti-miR-575 (Ambion) were used for transfection.   
Cell Proliferation Assay 
Cells (3 X 105) were seeded into 60 mm dishes and transfected the following day. Twenty-
four hours after transfection, cells were reseeded into a 96-well plate with 1000 cells/100 
uL in each well. Five replicates were used for each treatment group at each of five time 
points. The time points analyzed during this experiment were 24, 48, 72, 96, and 120 
hours post-transfection. Each day, cells were washed with 1X PBS and fixed with 4% 
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paraformaldehyde for 15 minutes. Cells were then stained with methylene blue for twenty 
minutes and were dried overnight.  The following day, 100 uL of solvent (10% acetic acid, 
40% H2O, 50% methanol) was applied to each well, and the plate was shaken for twenty 
minutes. The optical density (OD) value was then measured at an absorbance of 620 
nanometers. Experiments were repeated in triplicates.  
Colony Formation Assay 
Twenty-four hours following transfection, 100-500 cells in 2 mL were seeded into 6-well 
plates. Three replicates were used per treatment group. Cells were allowed to grow for 
10-14 days before harvesting. Cells were then washed with 1X PBS, and 0.5% crystal 
violet solution (2.5g crystal violet, 375 mL H2O, 125 mL methanol) was applied. Colonies 
were counted manually using a microscope (31). 
Migration Assay 
Twenty-four hours following transfection, 700 uL of DMEM media was placed in the lower 
chamber of each well in a 24-well plate to be used as a chemoattractant. 1 X 104 cells in 
300 uL of DMEM media were seeded into each the upper chamber of the transwell. Three 
replicates were used per treatment group. Forty-eight hours later, the upper chamber was 
scrubbed with a cotton swab to remove non-migratory cells. Cells were then stained with 
0.5% crystal violet solution (2.5g crystal violet, 375 mL H2O, 125 mL methanol) for 25 
minutes. Cells were rinsed with running water and allowed to dry overnight. Cells were 
counted the following day using a microscope.  
RT-qPCR Analysis of miRNA Expression 
Total RNA was isolated from GBM cells using the Trizol reagent (Invitrogen) and 
measured using a spectrophotometer (ThermoFisher). Total RNA (100 ng) was then 
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reverse transcribed using the TaqMan MicroRNA Reverse Transcription Kit (Applied 
Biosystems). The resulting cDNAs were then used in PCR to detect miR-575 expression 
levels by measuring reporter fluorescence (BioRad).  Primers and probes for miR-575 
and endogenous controls, RNU48 and RNU6B, were provided by the Taqman Small RNA 
Assay (Applied Biosystems). Experiments were performed in triplicates and analysis 
completed using the BioRad CFX Manager software. 
RT-qPCR Analysis of mRNA Expression 
Total RNA was isolated from GBM cells using Trizol (Invitrogen) and measured using a 
spectrophotometer (ThermoFisher). Total RNA (1000 ng) was then reverse transcribed 
using the High Capacity RNA to cDNA kit (Applied Biosystems). cDNA was then amplified 
by PCR using SYBR Green master mix (Qiagen) and primers for BLID (F: 5’-
ATGATGTTGTGTTTGGAGAAAAGA-3’; R: 5’-GCTTTGCATAAGCACGGTGTTA-3’), 
p27 (F: 5’-TGGAGAAGCACTGCAGAGAC-3’; R: 5’-GCGTGTCCTCAGAGTTAGCC-3’), 
KLF6 (F: 5’-ATCAGCCCTCTTTTCCGGTG-3’; R: 5’-TTCTTCTCTTCGGTCCGCTG-3’), 
SCAI (F: 5’-CAGAGGTTCTGGTGATAGCAGT-3’; R: 5’-CCAAGACTTGTCGATGCTGC-
3’), WDFY3 (F: 5’-GGAAATGCTCCGCCGAATACAA-3’; R: 5’-
CTCTACTGGCTTCTTCACTCTG-3’) and TSG101 (F: 5’-
AGTCTGACTGTGGGTGTTTC-3’; R: 5’-TATGGCTACTGGACACATAC-3’) (Invitrogen). 
GAPDH was used as endogenous control (Invitrogen). Experiments were completed in 
triplicate.  
Western Blot 
Western blot was performed for BLID and p27 protein, with GAPDH and Lamin-B as 
endogenous controls. Proteins were isolated using RIPA buffer (Invitrogen) and protease 
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inhibitors. Protein concentration was measured using the BCA Assay (ThermoFisher) with 
MikroWin 2000 software. Western blots were run using 4-15% Mini-Protean pre-cast gels 
(BioRad) at 120 V for one hour in 1 X running buffer (BioRad). Gels were then transferred 
to nitrocellulose blotting membranes in 1 X transfer buffer (BioRad) for 90 minutes at 0.3 
A in the 4oC room. Membranes were then blocked using 5% blocking milk in 1X Tris 
buffered saline with tween (TBS-T) for one hour. Membranes were then placed in primary 
antibodies at a 1:1000 concentration overnight in the 4oC room. Primary antibodies were 
purchased for the proteins BLID (Abcam), p27 (Abcam), Lamin-B (Cell Signaling), and 
GAPDH (Cell Signaling). Membranes were washed the following day with 1X TBS-T for 
15 minutes. Next, membranes were placed in 1:1000 polyclonal anti-mouse or anti-goat 
secondary antibodies conjugated with horseradish peroxidase for one hour (Abcam).  
After washing, ECL Plus Western Blotting Detection System (Millipore) was used for 
detection of horseradish peroxidase activity. Bands were quantified using ImageJ 
software.  
Plasmid Construction  
The primers for the BLID 3’UTR were first designed using Primer Blast (NCBI) and 
Ensembl genome browser. The forward primer is 5’-
CCGCTCGAGCGGTGAGTTAGGACAGATGCAGCAA-3’, and the reverse primer is 5’-
ATAAGAATGCGGCTAAACTATTGCAAGATTTGTTTTAATTAAATG-3’ (Invitrogen), 
including sites for the restriction enzymes XhoI and NotI. PCR was performed using the 
Platinum Taq Polymerase High Fidelity Kit (ThermoFisher) and genomic DNA previously 
isolated from U251 cells used as a template. A 1.5% agarose gel (1.5 g agarose, 100 mL 
1X TAE Buffer) was made with 5 uL of ethidium bromide. 5 uL of PCR product was used 
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in gel electrophoresis to confirm the correct product was synthesized. The gel was run 
again with 45 uL of PCR product. After the second time the gel was run, the DNA band 
was cut out and gel extraction was performed using the QIAquick Gel Extraction Kit 
(Qiagen). Next, the BLID 3’UTR and pCheck2-reporter luciferase vector were digested at 
37 °C using the restriction enzymes XhoI and NotI overnight. The digested products were 
then purified using the QIAquick PCR Purification Kit (Qiagen). Then, 25ng vector and 
75ng 3’UTR were ligated together using T4 DNA Ligase (Invitrogen). Transformation was 
then performed using max-efficiency DH5α competent cells protocol (ThermoFisher). 
Agar plates were made using 15 g of agar in 1 L of LB Broth. Ampicillin was added 1:1000 
dilution. 12 mL of the mixture was added to each 10 mL dish (Sigma). Following 
transformation, agar dishes were incubated in 37oC overnight. Clones were checked the 
following day and 3’UTR plasmids were then isolated using the QIA Spin Miniprep Kit 
(Qiagen). Digestion was performed again, and gel electrophoresis was used to confirm 
both the vector and the plasmid size. Then, 450 ng of DNA was used for Sanger 
sequencing to ensure the correct product was isolated. Three of the ten isolated clones 
were confirmed to be the correct BLID 3’UTR sequence and were later used for 
transfection in luciferase assays.  
Site-direct mutagenesis  
In order to synthesize the BLID 3’UTR mutant, the Q5 Site Directed Mutagenesis Kit 
(BioLabs) was used. The miR-575 binding site on BLID was mutated from 5’-
AACTGGCT-3’ to 5’CAATTGTT-3’ in a 4 bp mutation and confirmed with Sanger 
sequencing. The forward BLID 3’UTR 4 bp mutant primer is 5’-
TGTTAGTTAAAAGTAAATGGCATTTAATTAAAAC-3’, and the reverse primer is 5’-
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ATTGTATCCTTTTTAAAAATTTTATTGTTTCTC-3’. The miR-575 binding site on BLID 
was also mutated to 5’-CAATTGCT-3’ in a 3 bp mutation and confirmed with Sanger 
sequencing. The forward BLID 3’UTR 3 bp mutant primer is 5’-
TGCTAGTTAAAAGTAAATGGCATTTAATTAAAAC-3’, and the reverse primer is 5’-
ATTGTATCCTTTTTAAAAATTTTATTGTTTCTC-3’. 
Dual-Reporter Luciferase Assays 
The 3’UTR of BLID was constructed, inserted, and annealed to the pCheck2 luciferase 
vector. The 3’UTR of p27 was also inserted and annealed to the pCheck2 luciferase 
vector after purchase (OriGene). For BLID, cells were co-transfected with 50 pg of either 
miR-575 mimic or control and 2 ug of BLID wildtype or mutant 3’UTR plasmids. For p27, 
cells were co-transfected with either 50 pg miR-575 mimic or control and 2 ug of p27 
wildtype 3’UTR plasmids.  Forty-eight hours later, 5000-10000 cells/100 uL were 
reseeded into a 96-well plate, with five replicates per treatment group. 24 hours later, the 
dual-reporter luciferase assay (Promega) was performed, and the results were analyzed 
using a luminometer.  
Temozolomide Sensitivity Assay 
Twenty-four hours following transfection, cells were then reseeded into a 96-well plate. 
The following day each treatment group received temozolomide in concentrations of 0, 
10, 20, 50, 100, 250, or 500 uM. Seventy-two hours post-treatment, cells were fixed with 
4% paraformaldehyde and stained with methylene blue, according to the previously 
described protocol for the proliferation assay. Experiments were completed in triplicate.  
Radiation Sensitivity Assay  
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Twenty-four hours following transfection, cells were reseeded into 6-well plates with 
concentrations of 100, 200, 500, 1000 or 5000 cells in 2 mLs. Twenty-four hours later, 
each treatment group was irradiated with 0, 2, 4, 6 or 8 Gray (Gy), respectively. Cells 
were grown for 10-14 days and then stained using crystal violet method previously 
mentioned for the colony formation assay.  
Target Analysis 
Target genes were analyzed in silico using miRNA databases TargetScan 
(http://www.targetscan.org/vert_71), microrna.org (http://www.microrna.org) and miRDB 
(http://www.mirdb.org/). Databases were analyzed together using GeneVenn 
(http://genevenn.sourceforge.net/). Common targets among the databases were first 
analyzed, as well as targets that exhibited strong roles in oncogenesis based on previous 
publications (PubMed). 
Statistical Analysis 
For the univariable analysis, Nanostring data was used to determine correlation 
between Nanostring miRs and overall survival. miR-575 was median dichotomized, and 
the data were log2 transformed to determine the association between miR-575 
dichotomized expression and overall survival (univariable analysis). Other statistical 
analyses were performed using the software package SPSS 19.0 (SPSS, Chicago, USA). 
Student’s t-test was carried out to detect differential miRNA and mRNA expression. P-
values were calculated two-sided, and values less than 0.05 were considered to be 
statistically significant. Cox3 regression analysis was used for the multivariable analysis. 
Age, treatment, Kornofsky Performance Scale, and gender were used as covariables. 
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Results 
Overview 
Based on univariable and multivariable survival analyses, miR-575 demonstrated a strong 
negative correlation with overall survival in glioblastoma using a patient cohort from 
Utrecht (n=268). Following these analyses, a number of experiments were conducted to 
evaluate the physiological relevance of miR-575 in GBM cell lines. In addition to functional 
experimentation, a mechanistic study was conducted to determine potential target genes 
of miR-575. Specifically, p27/CDKN1B and BLID/BRCC2 were investigated in depth due 
to their promising value in silico analyses.  Lastly, a therapeutic study was conducted to 
determine if miR-575 played a role in radiation or temozolomide sensitivity, which are the 
current standards for GBM patient treatment.  
miR-575 Expression in GBM Cell Lines 
In order to select the most appropriate cell lines for experimentation, qRT-PCR was used 
to detect endogenous miR-575 expression in one normal human astrocyte (NHA) cell line 
and seven GBM cell lines (GBM30, LN18, LN229, T98G, U251, U87MG, and 
U87MG/EGFRvIII). In Figure 6, all seven GBM cell lines trend toward increased miR-575 
expression when compared to NHAs. It is important to note that our initial RT-qPCR 
revealed low endogenous miR-575 expression in LN229 and U251 cells and high 
endogenous miR-575 expression in U87MG cells. After noticing that there was a 
discrepancy in the control RNU6B, the experiment was repeated three times using a new 
control RNU48 to yield the results in Figure 6. 
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Cell Proliferation 
Since proliferation is a hallmark of tumorigenesis in GBM, we sought to determine if miR-
575 overexpression contributed to increased growth in GBM cell lines. Proliferation 
assays were conducted using LN229, U251, and U87MG cells. LN229 and U251 cells 
were used for miR-575 overexpression due to our initial RT-qPCR results indicating low 
endogenous miR-575 expression. U87MG cells were used for miR-575 inhibition due to 
their high endogenous miR-575 expression in the initial RT-qPCR. Figure 7 shows 
increased proliferation in both LN229 and U251 when transfected with miR-575 mimic (A; 
B). In addition, Figure 8 shows proliferation decreased in U87MG when treated with anti-
miR-575 inhibitor. Both results indicate that higher expression of miR-575 increases cell 
proliferation.   
Figure 6:  Relative miR-575 expression is shown normalized to normal human 
astrocytes (NHA). Transcript levels were normalized by RNU48. n=3. 
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Figure 7: LN229 and U251 cells were transiently transfected with miRNA negative 
control or miR-575 mimics, respectively. Cell proliferation assays were performed 
using methylene blue assay at different time points. n=5.  
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Colony Formation Assay 
Colony formation was assessed in the LN229, U251, and U87MG cell lines to determine 
if miR-575 expression affects growth of colonies in GBM cells. Colonies were imaged 10-
14 days following transfection with miR-575 mimic. Figure 9 shows increased colony 
formation in LN229 and U251 cells transfected with miR-575 mimic due to low 
endogenous miR-575 expression; U87MG cells were used for miR-575 inhibition due to 
high endogenous miR-575 expression. U87MG cells exhibit decreased colony formation 
when treated with the miR-575 inhibitor (Figure 10). Both results indicate that higher 
levels of miR-575 expression lead to increased colony formation in GBM cell lines. 
 
  
 
Figure 8: U87MG cells were transiently transfected with miRNA negative control or anti-
miR-575 inhibitor. Cell proliferation assays were performed using methylene blue 
assay at different time points. OD values at 48 and 120 hours are statistically significant 
using an unpaired t-test (p=0.0117; p=0.0066). n=5. 
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Migration Assay 
Migration assays were performed in LN229 and U251 cells to assess the effect of miR-
575 on migration in GBM cells. LN229 and U251 cells were used due to their low 
endogenous miR-575 expression. Migratory cells were stained, imaged, and quantified 
forty-eight hours after transfection with miR-575 mimic. Figure 11 shows increased 
migratory cell numbers in cells treated with mimic compared to the control LN229 and 
Figure 10: Colony formation assays were performed in U87MG cells after control or 
anti-miR-575 transfection. n=3  
miR-575 
mimic miR-NC 
LN229 
miR-575 
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U251 
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Figure 9: Colony formation assays were performed in LN229 and U251 cells after 
control or miR-575 mimic transfection. n=3. 
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U251 cell lines. Higher miR-575 expression is associated with a greater number of 
migratory cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Transwell migration assays were conducted in LN229 and U251 cells after 
transfection with miR-575 mimic. Numbers of migrated cells were quantified (A; B). 
Results were not statistically significant using unpaired t-test. n=3. 
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In Silico Target Gene Analysis 
 
In silico analysis was performed to determine potential target genes of miR-575 
using public available databases, miRDB, TargetScan, microrna.org, and miRTarBase. 
Databases were chosen based upon recommendations in miRNA bioinformatics reviews 
and previous miRNA publications (32, 33). The databases differ in input, platform, and 
algorithm used. TargetScan searches for conserved and non-conserved sites within the 
3’UTR of protein-coding regions, while taking into account the free energy of the RNA 
secondary structure (32). MirDB focuses on mature miRNA using a learning algorithm 
that includes an interactive interface for users. Lastly, microrna.org uses the miRanda 
algorithm to assess the miR’s ability to repress the target gene by utilizing 
complementarity and free energy analyses (34).  miRTarBase manually screens literature 
and uses a data mining technique to acquire current miRNA findings (35)  Six of the same 
target genes were found in at least three 
databases using the software 
GeneVenn (Figure 12). Furthermore, 
four additional gene targets 
(p27/Kip1/CDKN1B, BLID/BRCC2, 
SCAI, and WDFY3) were investigated 
for miR-575 binding sites that were 
found in at least one microRNA 
database. These genes were of 
particular interest due to their function in 
Figure 12: A Venn diagram showing the number of genes that possess a binding site 
for miR-575 belonging to each database, as well as the combination of databases 
(GeneVenn). 
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cancer and previous publications. While the Venn diagram did provide additional targets 
for investigation, we chose to focus on BLID and p27, which were only found in two miR 
databases, because of their roles in carcinogenesis. Notably, it was shown that miR-575 
targets the tumor-suppressor BLID in NSCLC, promoting tumorigenesis (26). Since the 
same miRNA may play a role in distinct cancer types, the relationship between miR-575 
and BLID in GBM was investigated.  
 
Correlation of miR-575 and target genes in GBM from the TCGA cohort 
Two-tailed Pearson correlation analysis was performed using The Cancer Genome Atlas 
(TCGA) to assess the correlation between miR-575 and CDKN1B (p27)/BLID in a GBM 
data set (n=159). Data were downloaded from Firebrowse. Figure 13A shows the 
optimized correlation between miR-575 and CDKN1B mRNA expression. Figure 13B 
shows the optimized correlation between miR-575 and BLID mRNA expression. miRNA 
expression should correlate inversely with target mRNA expression due to the established 
mechanism of action via mRNA degradation by miRNA. There is a significant negative 
correlation between miR-575 and CDKN1B (p=5.3 X 10-5). However, there does not 
appear to be a trend between miR-575 expression and BLID mRNA expression (p=0.32). 
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Figure 13: Pearson analysis was performed using the TCGA database. miR-575 
expression is compared to p27/CDKN1B (A) and BLID (B) mRNA expression. 
CDKN1B possess a statistically significant negative correlation with miR-575 (p = 5.3 
X 10-5). The correlation between BLID and miR-575 is not significant (p=0.32). 
A. 
B. 
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Target Genes of miR-575 
 
p27/CDKN1B 
mRNA Expression 
RT-qPCR was performed using cDNA from LN229 cells to determine p27 expression 
levels  after treatment with miR-575 mimic or control. LN229 cells were used for miR-575 
overexpression due to their low endogenous miR-575 expression. Figure 14 shows 
increased p27 gene expression in cells treated with miR-575 mimic.  Higher miR-575 
expression is associated with decreased levels of p27.  
 
Western Blot 
Western blot was used to detect protein expression of p27 in both LN229 and U251 
cells. Overexpression of miR-575 was performed in LN229 and U251 cells due to their 
low endogenous miR-575 expression. Figure 15 shows p27 protein expression at 
seventy-two hours post-transfection in LN229 and U251 cells. Both LN229 and U251 cells 
Figure 14: RT-qPCR was performed on cDNA from LN229 cells. P27 expression 
levels shown in response to transfection with either mimic or control; results 
normalized to GAPDH. Results were not significant using unpaired t-test.  
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exhibited a strong correlation of higher p27 expression in control cells compared to the 
mimic. Higher expression of miR-575 is associated with lower p27 protein levels.   
 
 
 
 
 
 
 
 
 
 
 
Dual-luciferase reporter assay 
Dual-luciferase reporter assays were performed using LN229 and U251 cell lines to 
determine if there was a direct relationship between miR-575 and p27 expression. LN229 
cells were used for miR-575 overexpression due to their low endogenous miR-575 
expression. Figure 16 shows the relative luciferase activity for three treatment groups in 
both cell lines. P27 3’UTR wildtype plasmid, containing Firefly and Renilla, was 
A. B. 
Figure 15:  Western blot of p27 protein expression in LN229 and U251 cells 72 
hours after transfection (A; C). GAPDH was used as endogenous control. 
Quantification in LN229 and U251 cells show downregulation of p27 when miR-575 
is overexpressed (B; D). 
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transfected with either control or miR-575 mimic. Both cell lines trend toward reduced 
luciferase activity when treated with miR-575 mimic at increasing doses. 
  
 
 
 
 
 
BLID 
mRNA Expression  
RT-qPCR was performed using cDNA from LN229 and U251 cells to determine BLID 
gene expression levels after transfection with miR-575 mimic, inhibitor, or miRNA 
negative control. LN229 cells were used for miR-575 overexpression due to their low 
endogenous levels of miR-575. Detection of BLID gene expression in both cells lines 
showed that cells treated with mimic had decreased BLID expression, while cells treated 
with inhibitor had increased BLID expression. Higher expression of miR-575 is correlated 
with lower BLID gene expression (Figure 17).  
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Figure 16: Dual-luciferase reporter assay in LN229 (A) and U251 (B) cells 72 hours 
post-transfection. Cells co-transfected with p27 3’UTR plasmid and miR-575 mimic 
exhibit down-regulation in luciferase activity compared to control. Results were not 
statistically significant using unpaired t-test. 
A. B. 
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Western Blot  
Western blot was performed using LN229 cells to detect BLID protein expression 
in cells treated with miR-575 mimic or control. Figure 18 shows imaging and quantification 
of BLID protein levels seventy-two hours after transfection. LN229 cells exhibit reduced 
BLID protein expression when miR-575 is overexpressed. Thus, overexpression of miR-
575 is associated with lower BLID protein expression. 
 
 
 
 
 
Figure 17: RT-qPCR was performed to measure BLID mRNA level in LN229 cells 
transfected with miRNA negative control or miR-575 mimic. 48 hours post-transfection, 
cells were harvested for RNA extraction. Results normalized to GAPDH.   
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Dual-luciferase reporter assay 
Dual-luciferase reporter assays were performed using LN229 cells to determine whether 
a BLID and miR-575 have a direct relationship. Figure 19 shows the relative luciferase 
activity of four distinct treatment groups, each receiving wildtype or mutant BLID 3’UTR 
plasmid co-transfected with either miR-control or miR-575 mimic. Figure 19 shows a 
reduction in luciferase expression for cells treated with 3’UTR wildtype BLID plasmid co-
transfected with miR-575 mimic. Reduction is rescued in the miR-575 mimic-treated 
group when cells are co-transfected with the BLID 3’UTR mutant.  
Figure 18: Western blot of BLID protein expression in LN229 cells (A). GAPDH was 
used as endogenous control. Quantification in LN229 cells show downregulation of 
BLID protein expression in mimic-treated cells compared to control (B).  
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Effect of miR-575 on temozolomide sensitivity  
Temozolomide sensitivity tests were performed using U87MG/EGFRvIII cells to 
assess chemotherapy response with varying levels of miR-575 expression. Figure 20 
shows the relative proliferation of U87MG/EGFRvIII cells in response to increasing doses 
of temozolomide. Cells were transfected with miR-575 mimic or control twenty-four hours 
before treatment. No significant difference was observed between the treatment group 
and control.  
Figure 19: Dual-luciferase reporter assay in LN229 cells. 72 hours post-transfection, 
relative luciferase activity based on treatment with wildtype or mutant BLID 3’UTR 
plasmid and miR-NC or miR-575 mimic. Cells treated with BLID 3’UTR wildtype 
plasmid exhibit a 20% reduction in luciferase activity compared with all other treatment 
groups. Results are not statistically significant. 
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Effect of miR-575 on radiation sensitivity  
1) miR-575 expression following radiation 
miR-575 expression following ionizing radiation (IR) was assessed by RT-qPCR using 
GBM30, T98G, and U251 cells. Figure 21 shows relative miR-575 expression in response 
to one 8 Gy dose of IR. In Figure 21 both T98G and U251 cells exhibit slightly upregulated 
miR-575 levels following IR, while GBM30 cells shows a decrease in miR-575 expression 
levels. The observed trend of miR-575 expression following IR is inconsistent across cell 
lines which could be due to heterogeneity between cell lines. 
 
 
 
Figure 20: A temozolomide assay was performed for U87MG-vIII cells. Shown is the 
relative proliferation of cells in response to increasing doses of temozolomide 72 hours 
following transfection. Results are not statistically significant.   
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2) Clonogenic Assay 
A clonogenic assay was performed using U251 cells to determine if miR-575 affects the 
sensitivity of GBM cells to radiation.  Figure 22 shows colony formation in control and 
miR-575 mimic-treated cells at varying IR doses. No significant difference in imaging was 
observed between the control and miR-575 mimic transfected group. Thus, miR-575 
expression does not appear to affect radiation sensitivity. This assay will be repeated in 
primary glioma cell lines.  
Figure 21: RT-qPCR was performed on cDNA from GBM30, T98G, and U251 cells 
following radiation with 8 Gy and a control group of 0 Gy. Relative miR-575 expression 
levels in response to treatment ten days after IR. Results are not statistically significant.  
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Figure 22: Clonogenic assay in U251 cells. Shown is colony formation following 
IR in control and miR-575 mimic-transfected cells. Two weeks following 
radiation, colonies were stained and imaged (A) and surviving fraction was 
quantified (B). Results were not statistically significant. 
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Discussion  
Key Findings 
Currently, new strategies to improve survival outcomes are desperately needed 
for GBM patients as median survival times remain poor (3). The Stupp protocol, which 
was implemented in 2005, still remains the standard of care after surgery for most patients 
(36).  Due to the heterogeneity presented in GBM tumors, more personalized medical 
approaches are necessary to improve overall survival. Epigenetic biomarkers, like 
miRNAs, are emerging as promising candidates to better characterize GBM patients into 
more refined prognostic groups (3). miRNAs have been shown to contribute to GBM 
tumor development and progression, and further insight to these biological mechanisms 
will likely help to identify novel targets for therapeutic intervention (8). To our knowledge, 
this study is the first to 1) identify miR-575 as a prognostic biomarker in GBM and to 2) 
show that miR-575 acts as an oncogene that directly targets the tumor-suppressor genes, 
p27 and BLID, in GBM. While the oncogenic effect of miR-575 has not been reported in 
GBM prior to this study, miR-575 has been shown to have both oncogenic and tumor 
suppressive effects in multiple other cancers. As previously discussed, high expression 
of miR-575 has been shown to promote cell proliferation, migration and invasion of 
NSCLC cells (26), but in breast cancer, miR-575 reduced cell growth and motility (27). 
Additionally, miR-575 signature profiles have been used to distinguish esophageal 
adenocarcinoma from Barrett’s esophagus, significantly impacting treatment modality 
chosen (28). While the function of miR-575 may vary across cancer types, its significance 
in tumorigenesis has been validated in multiple cancers, including gastric, lung, breast, 
and esophageal (26-28). 
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To further validate that increased miR-575 is associated with worse survival, we 
evaluated the physiological role of miR-575 in GBM in cell proliferation, colony formation, 
and migration. We utilized a synthetic miRNA mimic to overexpress miR-575 and a 
specific antisense oligonucleotide to inhibit miR-575 expression in GBM cells. 
Overexpression of miR-575 in vitro led to increased proliferation, colony formation, and 
migration, which are all hallmark mechanisms of tumorigenesis in GBM. These findings 
support the proposed oncogenic role of miR-575 in GBM.  
To investigate the underlying molecular mechanisms by which miR-575 promotes 
tumorigenesis, we identified potential target genes using in silico analyses of three miRNA 
databases in conjunction with current literature. p27 and BLID were identified as the most 
promising targets due to their frequency among miRNA databases and known roles in 
carcinogenesis. In order to further validate these targets in vitro, qPCR, western blotting, 
and luciferase assays were performed. Overexpression of miR-575 correlated with down-
regulation of p27 and BLID mRNA and protein levels. These results support our 
hypothesis by exhibiting downregulation of tumor-suppressor genes and protein 
expression in response to miR-575 overexpression. The correlation observed between 
miRNA and their target genes is a result of miRNA binding and degrading target gene 
mRNA or blocking translation. Through luciferase assays, we were able to support the 
idea that miR-575 binds directly to the 3’UTR of p27 and BLID mRNA to inhibit expression. 
p27 and BLID may be part of the same pathway or part of a global effect of this miR-575 
on GBM cells.  
While the relevance of p27 as a tumor-suppressor gene has been published in 
glioma, its relationship with miR-575 has not been documented to our knowledge (37-42). 
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One study reports the anti-proliferative effects of p27 in glioma cells through activation by 
CPEB1 (cytoplasmic element binding protein 1). CPEB1 is downregulated in GBM and 
participates in cell cycle by controlling mRNA translation efficiency via the 3’UTR (39).  
Additionally, increased p27 expression is shown to improve survival in glioma stem cells 
in vivo via the FOXOA3/Akt pathway. Dephosphorylation of FOXOA3 and Akt lead to 
increased p27 expression as a result of CLK2 (Cdc-like kinase 2) depletion (38).  Both 
studies support the tumor-suppressive function of p27 in GBM. Additionally, one study 
showed that application of p27 gene therapy could have a significant impact on malignant 
glioma treatment. In this study, a p27 adenovirus inhibited tumor progression in vitro (37). 
p27 plays a significant role in cell cycle and tumorigenesis, and it is crucial to identify 
more miRNAs that target it to widen alternative treatment options.   
Additionally, the miR-575/BLID axis was reported in NSCLC, but has yet to be 
validated in GBM prior to our study (26). miR-575 also decreased proliferation, colony 
formation, and migration in NSCLC cells as in our study. A recent study showed that BLID 
(BRCC2) inhibited metastasis in breast cancer by down-regulating the Akt pathway (43). 
To explore the potential role of miR-575 in therapeutic sensitivity, clonogenic and 
cell viability assays were performed which revealed no effect of miR-575 on 
radiosensitivity or chemosensitivity, respectively. Based on our findings, miR-575 
appears to serve as a prognostic biomarker in GBM, but its effects are independent of 
treatment and therefore do not promote resistance or sensitivity. 
Limitations 
This study utilizes GBM the cell lines LN229, U251, and U87, which are cultured 
cells. Recently, it has been discovered that primary cell lines, undifferentiated and stem-
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like, better retain their original genotype and more accurately represent the human GBM 
phenotype (44). Thus, our study supports miR-575 as a prognostic biomarker in GBM, 
but in order to confirm our findings, in vitro experimentation using primary glioma stem-
like cells and in vivo studies should be conducted.  
Additionally, as in other miRNA therapeutic studies, challenges regarding the 
ability of miRNAs to cross the blood-brain barrier and target a specific cell type remain. 
While miR-575 may be used individually as a prognostic biomarker after further validation, 
other studies have indicated that there are limitations in using a single miRNA to 
determine prognosis. MiRNA expression levels can change as a result of treatment and 
some miRNAs are implicated in multiple cancers. These studies suggest using miRNA 
panels, composed of many miRNAs, to obtain better sensitivity and specificity (8). miR-
575 may be used to develop a prognostic miRNA signature in future studies. 
While miRNAs have been identified as promising biomarker candidates, their role 
as potential therapeutic targets warrants careful examination of off-target effects that may 
lead to adverse side effects. For example, differences in PCR annealing temperatures 
and physiological temperatures may cause anti-miRs to anneal imperfectly to unwanted 
target gene areas and cause adverse side effects. Due to the potential for off-target 
effects in miRNA therapy, individual gene targets such as p27 or BLID may serve as 
better therapeutic interventions. Despite therapeutic challenges, miRNAs are excellent 
resources to detect the activity of pathways implicated in GBM tumor progression. 
While our physiological data is compelling, the mechanistic data requires further 
experimentation to confirm p27 and BLID as targets of miR-575. We have not yet mutated 
the p27 plasmid to confirm the reduction we observed using the p27 wildtype plasmid. 
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Furthermore, the reduction in luciferase activity for both target genes was modest, so we 
plan to replicate this experiment in additional cell lines to confirm the direct relationship 
between miR-575 and its target genes.  
Lastly, regarding our clinical data, tissues were only obtained from one cohort, so 
further validation in an independent cohort would strengthen our study’s clinical relevance 
and is warranted to ascertain the future role of miR-575 as a prognostic biomarker.  
Future Directions  
While our study provides in vitro evidence for miR-575 as an oncogene in GBM, 
experiments should be replicated in primary glioma cell lines, which more closely adhere 
to human phenotypes, before proceeding with in vivo experimentation. Additionally, we 
plan to further validate the putative targets p27 and BLID due to the discrepancies we 
observed in mRNA and protein expression. We plan to also pursue an in vivo study to 
further validate the oncogenic role of miR-575 and support our findings of its potential as 
a biomarker in GBM. 
Additionally, we identified other potential target genes in silico, but we have not yet 
attempted to validate these genes in vitro. These genes, including KLF6, SCAI, WDFY3, 
and TSG101, are all tumor-suppressor genes and are promising candidates to explore 
due to their roles in tumorigenesis. Of these, KLF6 and SCAI have been previously 
published in glioma (45, 46). 
Regarding the therapeutic role of miR-575, our results indicate that miR-575 has 
no effect on radiosensitivity and chemosensitivity, but further experimentation is required 
to confirm this finding. For chemosensitivity, cell viability assays after temozolomide 
treatment would need to be replicated in additional cell lines. Additionally, this result would 
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need to be confirmed by using an apoptosis assay with an accompanying western blot 
assaying apoptosis proteins, cleaved caspase-3 and cleaved caspase-9. For the 
clonogenics assay experiments such as comet assay or γ-H2AX foci assay should be 
conducted using additional cell lines to confirm our findings.  
 In conclusion, our study is the first to identify miR-575 as a biomarker in GBM 
which is significantly correlated with worse overall survival in a clinical cohort. We propose 
that miR-575 promotes tumor progression, in part, via direct-targeting of p27 and BLID. 
Our data suggest miR-575 may be used alone or with other molecular/clinical factors to 
better characterize GBMs thereby contributing to a personalized medicine approach. 
Additionally, our study provided insight into the mechanisms of tumor progression in GBM 
and identified additional promising targets for future therapies. 
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Conclusion 
Based on clinical data suggesting a negative correlation between miR-575 
expression and overall survival in GBM, this study was conducted to validate the 
oncogenic role of miR-575 in GBM. Using in vitro experimentation, we were able to show 
that overexpression of miR-575 increased proliferation, colony formation, and migration 
in GBM cell lines. Additionally, we identified two promising targets, p27 and BLID, that 
could serve as alternative points of therapeutic intervention in this tumor progression 
pathway. However, we did not find that miR-575 plays a role in radiation or chemotherapy 
sensitivity. Further analyses are needed to confirm these putative targets of miR-575 and 
to confirm that miR-575 does not affect therapeutic resistance in GBM. We postulate that 
miR-575 is a likely biomarker in GBM that acts in part by downregulating p27 and BLID. 
Importantly, this investigation of miR-575 provides further insight into tumor progression 
in GBM, which can be utilized to identify new targets for future treatments. 
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